Vaccinations in Patients Receiving Systemic Drugs for Skin Disorders: What Can We Learn for SARS-Cov-2 Vaccination Strategies?
Speeckaert ReinhartJo LambertLuis PuigMarijn SpeeckaertHilde LapeereSofie De SchepperNanja van GeelPublished in: Drugs in R&D (2021)
Large-scale vaccination strategies are currently being deployed against severe acute respiratory syndrome coronavirus-2 (SARS-Cov-2). Whether systemic medication for skin diseases affects the efficacy of vaccination and whether temporary interruption or extension of the dosing interval is necessary is under debate. Most immunomodulating/immunosuppressive drugs only affect vaccine-induced immune responses to a limited or moderate extent, preserving sufficient immunity in most patients. Mycophenolate mofetil, Janus kinase inhibitors, and rituximab require a more cautious approach, and judicious timing of vaccination might be appropriate in patients receiving these treatments. It should be noted that, for most drugs except methotrexate, data on the length of the interruption period to restore vaccine-induced immune responses to normal levels are either very limited or absent. In these cases, only the drug half-life can be used as a practical guideline. In most patients, systemic medication can be continued through the vaccination process, although case-by-case decisions can be considered.
Keyphrases
- sars cov
- respiratory syndrome coronavirus
- immune response
- end stage renal disease
- drug induced
- ejection fraction
- newly diagnosed
- chronic kidney disease
- healthcare
- prognostic factors
- coronavirus disease
- high dose
- adverse drug
- high glucose
- emergency department
- diffuse large b cell lymphoma
- high intensity
- oxidative stress
- low dose
- inflammatory response
- wound healing
- toll like receptor
- deep learning
- artificial intelligence